FIELD: food industry; medicine.
SUBSTANCE: present invention relates to use of a composition containing D-psicose, for inhibition of absorption of consumed lipids, increased dedication of consumed lipids or both, methods of inhibiting absorption of consumed lipids in a subject, increasing output of consumed lipids in a subject or both, a method for inhibiting fatty acid synthase activity in a subject, method for preventing, reducing intensity or treating hyperlipidemia, atherosclerosis, fatty hepatosis or a combination thereof. Disclosed methods and use include administering a composition containing D-psicose, to a subject, of which one is being fed with lipids, where D-psicose is introduced in amount of 20 to 30 weight parts relative to 100 weight parts of lipids consumed by the individual.
EFFECT: novel effective methods and use of a composition containing D-psicose, for preventing or treating diseases and conditions associated with lipid metabolism disorders.
7 cl, 11 ex, 3 tbl, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR MODULATING INTESTINAL MICROBIOTA | 2017 |
|
RU2738265C2 |
| SYMBIOTIC COMPOSITION FOR PREVENTION OF METABOLIC DISORDERS | 2018 |
|
RU2771744C2 |
| SYNBIOTIC COMPOSITION FOR PREVENTION OF METABOLIC DISORDERS | 2018 |
|
RU2771716C2 |
| CALEBIN A FOR HEPATIC STEATOSIS | 2015 |
|
RU2643297C2 |
| TREATMENT OF LIVER, BILE DUCT AND PANCREATIC DISORDERS | 2017 |
|
RU2740913C2 |
| NEW APPLICATIONS AND METHODS | 2017 |
|
RU2765804C2 |
| FOOD PRODUCT FOR DIABETICS | 2005 |
|
RU2380983C2 |
| USE OF COMPOSITIONS CONTAINING BIFIDOBACTERIUM ANIMALIS SSP. LACTIS LMG P-28149 | 2015 |
|
RU2673341C2 |
| METHOD OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) WITH USING CYSTEAMINE PRODUCTS | 2008 |
|
RU2498795C2 |
| COMPOSITION AND USE OF ARGININE-DEPLETING AGENTS IN CANCER, OBESITY, METABOLIC DISORDERS AND RELATED COMPLICATIONS AND COMORBIDITIES | 2019 |
|
RU2826185C2 |
